<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289211</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125101300</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">2</safetyreportversion>
    <safetyreportid lang="en">JP-CELGENEUS-087-21880-12123349</safetyreportid>
    <primarysourcecountry>JP</primarysourcecountry>
    <occurcountry>JP</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20121229</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130118</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">JP-CELGENEUS-087-21880-12123349</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reportergivename>Kubota</reportergivename>
      <reporterfamilyname>Hagiwara</reporterfamilyname>
      <reportercountry>JP</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>Y-U</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19540912</patientbirthdate>
      <patientsex>1</patientsex>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10011474</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10047001</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10061105</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10001041</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10050452</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10000803</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10037410</patientepisodename>
      </medicalhistoryepisode>
      <medicalhistoryepisode>
        <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
        <patientepisodename>10061758</patientepisodename>
        <patientmedicalstartdateformat>610</patientmedicalstartdateformat>
        <patientmedicalstartdate>201101</patientmedicalstartdate>
      </medicalhistoryepisode>
      <patientdeath>
        <patientdeathdateformat>102</patientdeathdateformat>
        <patientdeathdate>20121216</patientdeathdate>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10037410</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">SUSPICION OF PULMONARY INFARCTION</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10037410</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10037410</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20121215</reactionstartdate>
        <reactionduration>1</reactionduration>
        <reactiondurationunit>804</reactiondurationunit>
        <reactionfirsttime>397</reactionfirsttime>
        <reactionfirsttimeunit>804</reactionfirsttimeunit>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">DEEP VEIN THROMBOSIS</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10051055</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10051055</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20121215</reactionstartdate>
        <reactionfirsttime>397</reactionfirsttime>
        <reactionfirsttimeunit>804</reactionfirsttimeunit>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20111031</testdate>
        <testname lang="en">INR</testname>
        <testresult>0.99</testresult>
        <lowtestrange>0.90</lowtestrange>
        <hightestrange>1.10</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20111031</testdate>
        <testname lang="en">HEMOGLOBIN</testname>
        <testresult>8.5</testresult>
        <testunit>g/dL</testunit>
        <lowtestrange>13.5</lowtestrange>
        <hightestrange>17.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20111031</testdate>
        <testname lang="en">PROTHROMBIN TIME</testname>
        <testresult>11.8</testresult>
        <testunit>secs</testunit>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20111031</testdate>
        <testname lang="en">PLATELET COUNT</testname>
        <testresult>132</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>150</lowtestrange>
        <hightestrange>350</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20111031</testdate>
        <testname lang="en">APTT</testname>
        <testresult>30</testresult>
        <testunit>secs</testunit>
        <lowtestrange>22.0</lowtestrange>
        <hightestrange>37.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20111031</testdate>
        <testname lang="en">PT</testname>
        <testresult>11.8</testresult>
        <testunit>secs</testunit>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20111031</testdate>
        <testname lang="en">RED BLOOD CELL COUNT</testname>
        <testresult>2410</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>4300</lowtestrange>
        <hightestrange>5700</hightestrange>
      </test>
      <test>
        <testdateformat>610</testdateformat>
        <testdate>201209</testdate>
        <testname lang="en">PTT</testname>
        <testresult>26.7</testresult>
        <testunit>secs</testunit>
        <lowtestrange>22.0</lowtestrange>
        <hightestrange>37.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20120903</testdate>
        <testname lang="en">Red blood cell count</testname>
        <testresult>2970</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>4300</lowtestrange>
        <hightestrange>5700</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20120903</testdate>
        <testname lang="en">INR</testname>
        <testresult>1.09</testresult>
        <lowtestrange>.90</lowtestrange>
        <hightestrange>1.10</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20120903</testdate>
        <testname lang="en">Hemoglobin</testname>
        <testresult>10.5</testresult>
        <testunit>g/dL</testunit>
        <lowtestrange>13.5</lowtestrange>
        <hightestrange>17.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20120903</testdate>
        <testname lang="en">APTT</testname>
        <testresult>26.7</testresult>
        <testunit>secs</testunit>
        <lowtestrange>22.0</lowtestrange>
        <hightestrange>37.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20120903</testdate>
        <testname lang="en">Platelet count</testname>
        <testresult>185</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>150</lowtestrange>
        <hightestrange>350</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20120903</testdate>
        <testname lang="en">PT</testname>
        <testresult>12.6</testresult>
        <testunit>secs</testunit>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121001</testdate>
        <testname lang="en">PT</testname>
        <testresult>12.8</testresult>
        <testunit>secs</testunit>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121001</testdate>
        <testname lang="en">Red blood cell count</testname>
        <testresult>2690</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>4300</lowtestrange>
        <hightestrange>5700</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121001</testdate>
        <testname lang="en">APTT</testname>
        <testresult>28.7</testresult>
        <testunit>secs</testunit>
        <lowtestrange>22.0</lowtestrange>
        <hightestrange>37.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121001</testdate>
        <testname lang="en">Platelet count</testname>
        <testresult>129</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>150</lowtestrange>
        <hightestrange>350</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121001</testdate>
        <testname lang="en">INR</testname>
        <testresult>1.11</testresult>
        <lowtestrange>0.90</lowtestrange>
        <hightestrange>1.10</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121001</testdate>
        <testname lang="en">Hemoglobin</testname>
        <testresult>9.7</testresult>
        <testunit>g/dL</testunit>
        <lowtestrange>13.5</lowtestrange>
        <hightestrange>17.0</hightestrange>
      </test>
      <test>
        <testdateformat>610</testdateformat>
        <testdate>201211</testdate>
        <testname lang="en">PROTHROMBIN TIME</testname>
        <testresult>12.2</testresult>
        <testunit>secs</testunit>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121126</testdate>
        <testname lang="en">HEMOGLOBIN</testname>
        <testresult>10.8</testresult>
        <testunit>g/dL</testunit>
        <lowtestrange>13.5</lowtestrange>
        <hightestrange>17.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121126</testdate>
        <testname lang="en">PLATELET COUNT</testname>
        <testresult>142</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>150</lowtestrange>
        <hightestrange>350</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121126</testdate>
        <testname lang="en">APTT</testname>
        <testresult>28.4</testresult>
        <testunit>secs</testunit>
        <lowtestrange>22.0</lowtestrange>
        <hightestrange>37.0</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121126</testdate>
        <testname lang="en">PT</testname>
        <testresult>12.2</testresult>
        <testunit>secs</testunit>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121126</testdate>
        <testname lang="en">INR</testname>
        <testresult>1.07</testresult>
        <lowtestrange>0.90</lowtestrange>
        <hightestrange>1.10</hightestrange>
      </test>
      <test>
        <testdateformat>102</testdateformat>
        <testdate>20121126</testdate>
        <testname lang="en">RED BLOOD CELL COUNT</testname>
        <testresult>3020</testresult>
        <testunit>thousand per micro liter</testunit>
        <lowtestrange>4300</lowtestrange>
        <hightestrange>5700</hightestrange>
      </test>
      <test>
        <testdateformat>610</testdateformat>
        <testdate>201212</testdate>
        <testname lang="en">OXYGEN SATURATION</testname>
        <testresult>55</testresult>
        <testunit>%</testunit>
      </test>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">5 Milligram</drugdosagetext>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10051381</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20111114</drugstartdate>
        <drugstartperiod>397</drugstartperiod>
        <drugstartperiodunit>804</drugstartperiodunit>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10037410</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Probable</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10051055</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Probable</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>LENADEX</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext lang="en">2.8571 Milligram</drugdosagetext>
        <drugdosageform lang="en">Tablets</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10051381</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20101208</drugstartdate>
        <drugstartperiod>738</drugstartperiod>
        <drugstartperiodunit>804</drugstartperiodunit>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>2454002</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10037410</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Probable</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10051055</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Probable</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DECADRON</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">3 Milligram</drugdosagetext>
        <drugdosageform lang="en">Tablets</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10051381</drugindication>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>DEXAMETHASONE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10051055</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">10 Milligram</drugdosagetext>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>AMLODIPINE BESILATE</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">10 Milligram</drugdosagetext>
        <drugdosageform lang="en">Tablets</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10020772</drugindication>
        <activesubstance>
          <activesubstancename>AMLODIPINE BESILATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>DAIPHEN</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext lang="en">1.1429 Tablet</drugdosagetext>
        <drugdosageform lang="en">Tablets</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10049924</drugindication>
        <activesubstance>
          <activesubstancename>SULFAMETHOXAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>ACICLOVIR</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">400 Milligram</drugdosagetext>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>ACICLOVIR</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>TAKEPRON</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">15 Milligram</drugdosagetext>
        <drugdosageform lang="en">Tablets</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10017822</drugindication>
        <activesubstance>
          <activesubstancename>LANSOPRAZOLE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>BORTEZOMIB</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <activesubstance>
          <activesubstancename>Bortezomib</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>WARFARIN</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>1</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">1 Milligram</drugdosagetext>
        <drugdosageform lang="en">Tablets</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10043634</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20110228</drugstartdate>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20121215</drugenddate>
        <drugtreatmentduration>656</drugtreatmentduration>
        <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
        <activesubstance>
          <activesubstancename>WARFARIN</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>VICCLOX</medicinalproduct>
        <obtaindrugcountry>JP</obtaindrugcountry>
        <drugstructuredosagenumb>400</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">400 Milligram</drugdosagetext>
        <drugdosageform lang="en">Tablets</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10019944</drugindication>
        <activesubstance>
          <activesubstancename>ACICLOVIR</activesubstancename>
        </activesubstance>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">DEEP VEIN THROMBOSIS

(JAPAN) Initial information was received on 29Dec2012 from a physician regarding a 58 year old male who received Revlimid dose, duration unspecified from Jan2011 to unknown date and 5mg every other day for 21 day cycle from 14/Nov/2011 for indication of multiple myeloma. Other suspect  therapy included Lenadex 20mg/week and Decadron 3mg daily (both from unspecified date) for indication of multiple myeloma. Medical history included in 2006 the patient developed purpura of lower extremity for which Cryoglobulinaemia was diagnosed. In Dec2008: as generalized purpura emerged and caused acute renal failure, dialysis was performed. In 2009, Monoclonal protein (IgG) was detected and autologous peripheral blood stem cell transplant was performed for diagnosis of Cryoblobulinaemia due to MGUS/SMM. On unknown date Botezomib therapy was initiated because as patient met criteria for multiple myeloma. It was noted that in Jan2011 Revlimid was started due to worsening of multiple myeloma and that after start of Revlimid the Cryoglobulin disappeared and IgG decreased. Varicose veins of right lower leg also provided as history. Concomitant medications provided as Oxycodone, Amlodipine Besilate, Daiphen, Vicclox, Takepron.

ON 15Dec2012 the patient  experienced deep vein thrombosis (DVT) presenting with pain in leg in the morning, patient stayed home from work and in evening (approximately 1700 hours) the patient was discovered at home by wife,  experiencing heavy breathing, emergency services called and arrived at 18:30 hours to find patient with O2 saturation of 55%. At hospital treatment included intubation and vasopressor. Echo Doppler and Chest CT was not done. On 16Dec2012 at 1:35am the patient expired. Autopsy pending. Acute heart failure was diagnosed. Thrombosis of lower extremity was suspected.

Laboratory values provided as follows: On 31Oct2011 (baseline reported as start of Revlimid): Platelet count (PLT) - 13.2, Red blood cell count (RBC) - 241, Hemoglobin (HGB) - 8.5, International normalised ratio (INR) - 0.99, Prothrombin time (PT) - 11.8, Activated partial thromboplastin time (APTT) - 30. In Sep2012: PLT - 18.5, RBC - 297, HGB - 10.5, INR - 1.09, PT - 12.6, APTT - 26.7. In Oct2012: PLT - 12.9, RBC - 269, HGB - 9.7, INR - 1.11, PT - 12.8, APTT - 28.7. in Nov2012: PLT - 14.2, RBC - 302, HGB - 10.8, INR - 1.07, PT - 12.2, APTT - 28.4.

Comment by reporting physician: Pulmonary infarction was developed from deep vein thrombosis due to multiple myeloma and Revlimid/Dexamethasone therapy and worsened serious which resulted in death. Warfarin was prescribed, however the effect was not sufficient. Cryoglobulinaemia was also suspected.

The reporter's causal assessment was provided as follows:
DVT: Revlimid (suspected), Lenadex (suspected), Decadron (not provided).

Additional information will be requested.

Additional information was received on 08Jan2013 from a physician. Patient's date of birth provided. Start date of Revlimid 5mg every other day was confirmed to be 14Nov2011. No further information was provided. 

SUSPICION OF PULMONARY INFARCTION

Additional information was received on 18Jan2013 from the physician. 
Drug information was updated as follows:
LenaDex was started on 08/Dec2010, and concomitant medication warfarin was received from 28Feb2011 to 15Dec2012. 
Decadron was received for relapsed/refractory multiple myeloma.
The indications were reported for concomitant medications Amlodipine received for hypertension, warfarin for prophylaxis of thrombosis, Daiphen for prophylaxis of infection, Vicclox received for herpes, and Takepron for gastric ulcer.
The serious adverse event of suspicion of pulmonary infarction was added as adverse event occurring on 15Dec2012; and the outcome was death on 16Dec2012. 
The seriousness and outcome for the event of deep vein thrombosis were amended to not provided and unknown, respectively. 
No test finding was performed. 

On 31Oct2011 (baseline reported as start of Revlimid): Platelet count (PLT) (ref range 150-350 k/uL) 13.2, Red blood cell count (RBC) (ref range 4300-5700 k/uL) 241, Hemoglobin (HGB) (ref. range 13.5-17.0 g/dL) 8.5, International normalised ratio (INR) (ref range 0.90-1.10) 0.99, Prothrombin time (PT)  11.8 sec, Activated partial thromboplastin time (APTT) (ref range 22.0-37.0 sec)30. On 03Sep2012: PLT - 18.5, RBC - 297, HGB - 10.5, INR - 1.09, PT - 12.6, APTT - 26.7. On 01Oct2012: PLT - 12.9, RBC - 269, HGB - 9.7, INR - 1.11, PT - 12.8, APTT - 28.7. On 26Nov2012: PLT -14.2, RBC - 302, HGB - 10.8, INR - 1.07, PT - 12.2, APTT - 28.4.

The investigator assessed the causal relationship as follows:
Suspicion of pulmonary infarction: Revlimid (probable); LenDex (probable)</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and DEEP VEIN THROMBOSIS and DEATH DUE TO SUSPICION OF PULMONARY INFARCTION suggest that a causal relationship is possible, but underlying disease may provide an alternative explanation. A medical history of varicose veins of  lower extremity and Cryoglobulinemia may have been contributory for the event of DVT.  Additionally, co-suspect Lenadex and Decadron may have contributed to the event development. 

The event of death was now considered unlabeled in IB.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
